Donald Trump has signed a new executive order to speed up research on psychedelic drugs, raising hopes it could also help move long delayed cannabis reform in the United States.
The order supports studies on substances like psilocybin, MDMA, and ibogaine. It directs agencies such as the U.S. Food and Drug Administration to expand clinical trials and allow wider patient access under special programs. However, it does not change how these drugs are classified under federal law.
The move comes months after Trump called for cannabis to be reclassified. That effort has slowed, with the Drug Enforcement Administration still reviewing the proposal and no final decision in place.
Experts link drug policy delays to scientific, legal, and political hurdles. Still, some believe the new focus on medical research could offer a path forward.
The psychedelics industry has already reacted. Companies like Compass Pathways and Cybin saw stock gains after the announcement.
The order underscored ibogaine’s safety concerns and health risks, despite its mental health research. Industry leaders see this as a step to acceptance, requiring rigorous research and safety.
Psychedelics and cannabis stays transitional, with policymakers balancing benefits versus risks.
Related Readings:
